UTHR Stock Overview
A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
United Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$357.64 |
| 52 Week High | US$417.82 |
| 52 Week Low | US$208.62 |
| Beta | 0.55 |
| 1 Month Change | -3.47% |
| 3 Month Change | -0.053% |
| 1 Year Change | 62.65% |
| 3 Year Change | 69.80% |
| 5 Year Change | 313.12% |
| Change since IPO | 5,768.96% |
Recent News & Updates
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Dec 10
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Recent updates
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Dec 10United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Shareholder Returns
| UTHR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.7% | 0.7% | 0.6% |
| 1Y | 62.6% | -3.4% | 23.7% |
Return vs Industry: UTHR exceeded the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: UTHR exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| UTHR volatility | |
|---|---|
| UTHR Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: UTHR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: UTHR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,168 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
| UTHR fundamental statistics | |
|---|---|
| Market cap | US$16.07b |
| Earnings (TTM) | US$1.11b |
| Revenue (TTM) | US$2.76b |
14.4x
P/E Ratio5.8x
P/S RatioIs UTHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UTHR income statement (TTM) | |
|---|---|
| Revenue | US$2.76b |
| Cost of Revenue | US$304.80m |
| Gross Profit | US$2.45b |
| Other Expenses | US$1.34b |
| Earnings | US$1.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.88 |
| Gross Margin | 88.94% |
| Net Profit Margin | 40.31% |
| Debt/Equity Ratio | 6.6% |
How did UTHR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 22:56 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
United Therapeutics Corporation is covered by 37 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Birchenough | Barclays |
| Derek Taller | Benchmark Company |